BSE
524506

Coral Laboratories Limited

Drugs - Generic
Healthcare

Prices are adjusted according to historical splits.

Coral Laboratories Limited Stock Price

Vitals

Today's Low:
₹280.1
Today's High:
₹310
Open Price:
₹300
52W Low:
₹217
52W High:
₹368
Prev. Close:
₹298
Volume:
2112

Company Statistics

Market Cap.:
₹1.41 billion
Book Value:
323.772
Revenue TTM:
₹792.35 million
Operating Margin TTM:
11.02%
Gross Profit TTM:
₹288.55 million
Profit Margin:
15.16%
Return on Assets TTM:
0%
Return on Equity TTM:
0%

Company Profile

Coral Laboratories Limited had its IPO on under the ticker symbol 524506.

The company operates in the Healthcare sector and Drugs - Generic industry. Coral Laboratories Limited has a staff strength of 171 employees.

Stock update

Shares of Coral Laboratories Limited opened at ₹300 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹280.1 - ₹310, and closed at ₹283.6.

This is a -4.83% slip from the previous day's closing price.

A total volume of 2,112 shares were traded at the close of the day’s session.

In the last one week, shares of Coral Laboratories Limited have increased by +4.84%.

Coral Laboratories Limited's Key Ratios

Coral Laboratories Limited has a market cap of ₹1.41 billion, indicating a price to book ratio of 1.1559 and a price to sales ratio of 1.6875.

In the last 12-months Coral Laboratories Limited’s revenue was ₹792.35 million with a gross profit of ₹288.55 million and an EBITDA of ₹107.46 million. The EBITDA ratio measures Coral Laboratories Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Coral Laboratories Limited’s operating margin was 11.02% while its return on assets stood at 0% with a return of equity of 0%.

In Q2, Coral Laboratories Limited’s quarterly earnings growth was a positive 1253.2% while revenue growth was a positive 63.5%.

Coral Laboratories Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
11.1323
PEG

Its diluted EPS in the last 12-months stands at ₹33.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coral Laboratories Limited’s profitability.

Coral Laboratories Limited stock is trading at a EV to sales ratio of 1.748 and a EV to EBITDA ratio of 8.4368. Its price to sales ratio in the trailing 12-months stood at 1.6875.

Coral Laboratories Limited stock pays annual dividends of ₹5 per share, indicating a yield of 0.86% and a payout ratio of 5.95%.

Balance sheet and cash flow metrics

Total Assets
₹1.74 billion
Total Liabilities
₹118.60 million
Operating Cash Flow
₹-26147000.00
Capital Expenditure
₹19.45 million
Dividend Payout Ratio
5.95%

Coral Laboratories Limited ended 2024 with ₹1.74 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.74 billion while shareholder equity stood at ₹1.55 billion.

Coral Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹118.60 million in other current liabilities, 35726000.00 in common stock, ₹1.51 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹404.07 million and cash and short-term investments were ₹642.87 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

Coral Laboratories Limited’s total current assets stands at ₹1.24 billion while long-term investments were ₹0 and short-term investments were ₹238.79 million. Its net receivables were ₹234.21 million compared to accounts payable of ₹0 and inventory worth ₹125.04 million.

In 2024, Coral Laboratories Limited's operating cash flow was ₹-26147000.00 while its capital expenditure stood at ₹19.45 million.

Comparatively, Coral Laboratories Limited paid ₹0.06 in dividends in 2024.

Other key metrics

Current Trading Price
₹283.6
52-Week High
₹368
52-Week Low
₹217
Analyst Target Price

Coral Laboratories Limited stock is currently trading at ₹283.6 per share. It touched a 52-week high of ₹368 and a 52-week low of ₹368. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹259.99 and 200-day moving average was ₹270.33 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7539.4% of the company’s stock are held by insiders while 35% are held by institutions.

Frequently Asked Questions About Coral Laboratories Limited

The stock symbol (also called stock or share ticker) of Coral Laboratories Limited is 524506

The IPO of Coral Laboratories Limited took place on

Similar Industry Stocks (Drugs - Generic)

Last Price
Chg
Chg%
₹0.05
0
+0.2%
₹22.5
-2
-8.16%
₹2.63
-0.32
-10.85%
₹6.1
-0.1
-1.61%
₹20.5
0.73
+3.69%
₹19.51
-0.09
-0.46%
₹0.09
-0
-4.12%
₹70.6
0.56
+0.8%
₹132.13
1.29
+0.99%
HMT Limited (500191)
₹35.15
-1.85
-5%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/antiinflammatory, antispasmodic, anticold, antiallergic, antiasthmatic, antidiabetic, antiemetics, anthelmentic, thyroid, and antiprotozoal/antiamebic products; antimalarial drugs, antipsychotic drugs, gastro-intestinal drugs, kits, muscle relaxants, cough suppressant/expectorant products, cardiovascular medicines, oral antiseptic preparations, mouthwashes, calcium preparations, and appetizers; and nutritional, protein, and iron supplements, as well as other products. It also provides cephalosporin, beta lactam, and lyophilized injectable products; eye/ear/nose drops; nasal sprays and metered dose inhales; and large volume parenteral products. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/phytochemicals, multivitamins, and nutrients, as well as OTC products. It provides its products in various dosage forms, including tablets, capsules, low RH facilities, liquid orals, liquids and powders, dry syrups, drops, ointment and creams, gels and lotions, granules powders, injectables, nasal sprays, and suppositories. Coral Laboratories Limited was incorporated in 1994 and is headquartered in Mumbai, India.

Address

#3B, Patanwala Industrial Estate, Mumbai, India, 400086